Supernus, Inc. (SUPN): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$10.00M
Year ended 2025-12-31
$7.00M
Trailing 12 months to 2026-09-30
-14.5%
3-year compound annual growth
$16.00M2022-12-31: $16.00M2023-12-31: $15.00M2024-12-31: $16.00M2025-12-31: $10.00M$10.00M
2022-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$10.00M-37.5%2026-02-26, From 2025-01-01
2024-12-31$16.00M+6.7%2026-02-26, From 2024-01-01
2023-12-31$15.00M-6.3%2026-02-26, From 2023-01-01
2022-12-31$16.00Mn/a2025-03-03, From 2022-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Supernus, Inc. (SUPN)2025-12-31$10.00M-37.5%
Prestige Consumer Healthcare Inc. (PBH)2026-03-31$31.27M+3.6%
Alkermes plc. (ALKS)2025-12-31$27.16M-4.8%
Phibro Animal Health Corp (PAHC)2026-06-30$51.51M+13.0%
Madrigal Pharmaceuticals, Inc. (MDGL)2025-12-31$1.51M+37.4%
PTC Therapeutics, Inc. (PTCT)2025-12-31$38.81M-48.7%
ANI Pharmaceuticals Inc (ANIP)2025-12-31$91.42M+35.0%
Corcept Therapeutics Inc (CORT)2025-12-31$1.15M+44.5%
Emergent BioSolutions Inc. (EBS)2025-12-31$95.80M-11.9%

Compare SUPN, PBH, ALKS, PAHC side by side · Screen every company in Pharmaceutical Preparations ↗